NCT05651932 2026-02-10
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
K36 Therapeutics, Inc.
Phase 1 Recruiting
Clinical Trials
4 trialsNCT06152575 2026-02-03
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Pfizer
Phase 3 Recruiting
NCT04271644 2025-02-25
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Recruiting
NCT04776330 2025-02-25
a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Recruiting